
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
BAJAJ BROKING
Dr. Reddy’s Laboratories delivered a strong Q2 FY24-25, showcasing substantial revenue growth with consolidated revenue reaching ₹80,162 million. However, profit after tax saw a slight decline. Explore detailed insights and segment breakdown.
Dr. Reddy’s Laboratories reported consolidated revenue of ₹80,162 million for Q2 FY24-25, a year-over-year increase of 17% and a quarter-over-quarter growth of 4%. Despite higher costs, the gross profit margin remained strong, supporting Dr. Reddy's growth across its generics and emerging markets segments.
The net profit after tax reached ₹13,415 million, a 9% decline YoY, mainly due to one-time expenses, including acquisition-related costs and tax adjustments. This stable financial performance, combined with strategic investments in research and partnerships, underscores Dr. Reddy’s ongoing commitment to operational efficiency and expansion into emerging markets.
Dr. Reddy’s Q2 results exceeded industry expectations, with a substantial increase in revenue from its generics segment, especially in North America and emerging markets. This growth aligns with the sector’s robust demand for generic drugs, while slight declines in profit were anticipated due to higher SG&A and R&D investments.
G V Prasad, Co-Chairman & MD of Dr. Reddy’s, noted, "We delivered another good quarter and maintained the growth momentum across businesses. We made progress on our future growth drivers, operationalized our venture with Nestle and completed the acquisition of Nicotinell® and related brands. We will continue to drive efficiency, strengthen our core businesses, and positively impact patient lives through science and innovation."
Metric | Q2 FY24-25 | Q1 FY24-25 | Q2 FY23-24 |
Revenue (₹ million) | 80,162 | 76,727 | 68,802 |
Gross Profit (₹ million) | 47,769 | 46,344 | 40,368 |
EBITDA (₹ million) | 22,803 | 21,599 | 21,813 |
PAT (₹ million) | 13,415 | 13,920 | 14,800 |
EPS (₹) | 15.07 | 16.72 | 17.80 |
Selling & Administrative Expenses | 23,007 | 22,691 | 18,795 |
R&D Expenses (₹ million) | 7,271 | 6,193 | 5,447 |
Check out Dr Reddy's Lab's past performances in previous quarters and financial years.
Dr. Reddy’s Q2 results for FY24-25 demonstrate a solid performance with significant revenue growth across core segments. Despite challenges from rising costs and tax adjustments, the company has maintained a stable profit margin, underscoring its resilience and strategic focus. With new acquisitions, partnerships, and a strong presence in emerging markets, Dr. Reddy’s is well-positioned for sustained growth in the coming quarters.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading